Conjugated therapeutic proteins as a treatment for bacteria which trigger cancer development
Mohamed Halawa1, Precious M Newman1, Tope Aderibigbe1
1Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA.
Abstract:
In recent years, an increasing amount of research has focused on the intricate and complex correlation between bacterial infections and the development of cancer. Some studies even identified specific bacterial species as potential culprits in the initiation of carcinogenesis, which generated a great deal of interest in the creation of innovative therapeutic strategies aimed at addressing both the infection and the subsequent risk of cancer. Among these strategies, there has been a recent emergence of the use of conjugated therapeutic proteins, which represent a highly promising avenue in the field of cancer therapeutics. These proteins offer a dual-targeting approach that seeks to effectively combat both the bacterial infection and the resulting malignancies that may arise because of such infections. This review delves into the landscape of conjugated therapeutic proteins that have been intricately designed with the purpose of specifically targeting bacteria that have been implicated in the induction of cancer.
Insights
Researchers are exploring conjugated therapeutic proteins to target bacteria linked to cancer. This dual-action approach aims to combat infections and prevent cancer development, offering a novel strategy for cancer therapeutics.
Area of Science:
- Oncology
- Microbiology
- Biotechnology
Background:
- Growing evidence links bacterial infections to cancer development.
- Specific bacterial species are implicated as potential carcinogens.
- There is a need for innovative therapies targeting both infection and cancer risk.
Purpose of the Study:
- To review conjugated therapeutic proteins for targeting bacteria involved in cancer induction.
- To explore dual-targeting strategies against bacterial infections and associated malignancies.
Main Methods:
- Literature review of research on conjugated therapeutic proteins.
- Analysis of studies identifying bacteria linked to carcinogenesis.
- Examination of therapeutic protein designs for dual targeting.
Main Results:
- Conjugated therapeutic proteins show promise for dual-action cancer therapy.
- These proteins are designed to target specific bacteria implicated in cancer.
- The approach addresses both infectious agents and potential malignancies.
Conclusions:
- Conjugated therapeutic proteins represent a promising strategy in cancer therapeutics.
- Targeting bacteria implicated in cancer offers a novel approach to prevention and treatment.
- Further research into these dual-targeting agents is warranted.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF


